Description
Gamifant (emapalumab-lzsg) is a medication used to treat primary hemophagocytic lymphohistiocytosis (HLH), a rare and life-threatening condition that affects the immune system and blood cells. It is a monoclonal antibody that targets interferon-gamma, a cytokine that plays a role in inflammation in the body, and is administered by injection.
Uses:
Gamifant is used to treat adult and pediatric patients who have been diagnosed with primary HLH and have not responded to other treatments. Primary HLH is a genetic condition that affects the immune system and can cause organ damage, coagulopathy, and inflammation.
Storage Conditions:
Gamifant should be stored in the refrigerator at a temperature of 36°F to 46°F (2°C to 8°C) in its original carton. The medication should not be frozen, shaken, or diluted. If necessary, the medication may be kept at room temperature below 77°F (25°C) for up to 7 days in its original carton.
Mechanism of Action:
Gamifant works by binding to interferon-gamma and preventing its activity in the body. Interferon-gamma plays a role in inflammation and immune responses in the body, and by blocking its activity, Gamifant reduces inflammation, improves coagulopathy, and reduces organ damage in patients with primary HLH.
How to Use:
Gamifant is administered as a slow intravenous push injection by a healthcare provider. The dosage and frequency of treatment are determined by the healthcare provider based on the patient’s weight. The initial dose is typically 1 mg/kg followed by maintenance doses of 0.5 mg/kg every 3 days.
Precautions:
Before receiving Gamifant, patients should inform their healthcare provider of any allergies, medical conditions, and medications they are currently taking. Gamifant may increase the risk of infections, and patients should be monitored for signs of infection while receiving the medication. Patients with a history of tuberculosis or other infections may not be able to receive Gamifant.
Drug Interactions:
Gamifant may interact with drugs that affect the immune system, including immunosuppressive agents and live vaccines. Patients should inform their healthcare provider of any medications they are taking before receiving Gamifant.
Contraindications:
Gamifant is contraindicated in patients with known hypersensitivity to emapalumab-lzsg or any of its components.
Overdose:
In the event of an overdose, patients should contact their healthcare provider. There is no specific antidote for Gamifant.
Adverse Reactions:
The most common adverse reactions reported with Gamifant include infections, infusion-related reactions, elevation of liver enzymes, and hypersensitivity reactions. Patients should report any adverse reactions to their healthcare provider.
Overall, Gamifant is a monoclonal antibody medication used to treat primary HLH by blocking the activity of interferon-gamma in the body. The medication is administered by a healthcare provider as a slow intravenous push injection, and the dosage and frequency of treatment are determined based on the patient’s weight. Patients should inform their healthcare provider of any allergies, medical conditions, and medications they are taking, and should be monitored for signs of infection while receiving the medication. Gamifant may cause infusion-related reactions, elevation of liver enzymes, and hypersensitivity reactions.
Reviews
There are no reviews yet.